Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing

Saeam Shin, Yoonjung Kim, Seoung Chul Oh, Nae Yu, Seung Tae Lee, Jong Rak Choi, Kyung A. Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In this study, we validated the analytical performance of BRCA1/2 sequencing using Ion Torrent's new bench-top sequencer with amplicon panel with optimized bioinformatics pipelines. Using 43 samples that were previously validated by Illumina's MiSeq platform and/or by Sanger sequencing/multiplex ligation-dependent probe amplification, we amplified the target with the Oncomine™ BRCA Research Assay and sequenced on Ion Torrent S5 XL (Thermo Fisher Scientific, Waltham, MA, USA). We compared two bioinformatics pipelines for optimal processing of S5 XL sequence data: the Torrent Suite with a plug-in Torrent Variant Caller (Thermo Fisher Scientific), and commercial NextGENe software (Softgenetics, State College, PA, USA). All expected 681 single nucleotide variants, 15 small indels, and three copy number variants were correctly called, except one common variant adjacent to a rare variant on the primer-binding site. The sensitivity, specificity, false positive rate, and accuracy for detection of single nucleotide variant and small indels of S5 XL sequencing were 99.85%, 100%, 0%, and 99.99% for the Torrent Variant Caller and 99.85%, 99.99%, 0.14%, and 99.99% for NextGENe, respectively. The reproducibility of variant calling was 100%, and the precision of variant frequency also showed good performance with coefficients of variation between 0.32 and 5.29%. We obtained highly accurate data through uniform and sufficient coverage depth over all target regions and through optimization of the bioinformatics pipeline. We confirmed that our platform is accurate and practical for diagnostic BRCA1/2 testing in a clinical laboratory.

Original languageEnglish
Pages (from-to)34858-34866
Number of pages9
JournalOncotarget
Volume8
Issue number21
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Workflow
Genetic Testing
Computational Biology
Ions
Nucleotides
Multiplex Polymerase Chain Reaction
Software
Binding Sites
Sensitivity and Specificity
Research

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Shin, Saeam ; Kim, Yoonjung ; Oh, Seoung Chul ; Yu, Nae ; Lee, Seung Tae ; Choi, Jong Rak ; Lee, Kyung A. / Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing. In: Oncotarget. 2017 ; Vol. 8, No. 21. pp. 34858-34866.
@article{b0491e22f42540a79967a71d5ee92942,
title = "Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing",
abstract = "In this study, we validated the analytical performance of BRCA1/2 sequencing using Ion Torrent's new bench-top sequencer with amplicon panel with optimized bioinformatics pipelines. Using 43 samples that were previously validated by Illumina's MiSeq platform and/or by Sanger sequencing/multiplex ligation-dependent probe amplification, we amplified the target with the Oncomine™ BRCA Research Assay and sequenced on Ion Torrent S5 XL (Thermo Fisher Scientific, Waltham, MA, USA). We compared two bioinformatics pipelines for optimal processing of S5 XL sequence data: the Torrent Suite with a plug-in Torrent Variant Caller (Thermo Fisher Scientific), and commercial NextGENe software (Softgenetics, State College, PA, USA). All expected 681 single nucleotide variants, 15 small indels, and three copy number variants were correctly called, except one common variant adjacent to a rare variant on the primer-binding site. The sensitivity, specificity, false positive rate, and accuracy for detection of single nucleotide variant and small indels of S5 XL sequencing were 99.85{\%}, 100{\%}, 0{\%}, and 99.99{\%} for the Torrent Variant Caller and 99.85{\%}, 99.99{\%}, 0.14{\%}, and 99.99{\%} for NextGENe, respectively. The reproducibility of variant calling was 100{\%}, and the precision of variant frequency also showed good performance with coefficients of variation between 0.32 and 5.29{\%}. We obtained highly accurate data through uniform and sufficient coverage depth over all target regions and through optimization of the bioinformatics pipeline. We confirmed that our platform is accurate and practical for diagnostic BRCA1/2 testing in a clinical laboratory.",
author = "Saeam Shin and Yoonjung Kim and Oh, {Seoung Chul} and Nae Yu and Lee, {Seung Tae} and Choi, {Jong Rak} and Lee, {Kyung A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.16799",
language = "English",
volume = "8",
pages = "34858--34866",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "21",

}

Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing. / Shin, Saeam; Kim, Yoonjung; Oh, Seoung Chul; Yu, Nae; Lee, Seung Tae; Choi, Jong Rak; Lee, Kyung A.

In: Oncotarget, Vol. 8, No. 21, 01.01.2017, p. 34858-34866.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing

AU - Shin, Saeam

AU - Kim, Yoonjung

AU - Oh, Seoung Chul

AU - Yu, Nae

AU - Lee, Seung Tae

AU - Choi, Jong Rak

AU - Lee, Kyung A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In this study, we validated the analytical performance of BRCA1/2 sequencing using Ion Torrent's new bench-top sequencer with amplicon panel with optimized bioinformatics pipelines. Using 43 samples that were previously validated by Illumina's MiSeq platform and/or by Sanger sequencing/multiplex ligation-dependent probe amplification, we amplified the target with the Oncomine™ BRCA Research Assay and sequenced on Ion Torrent S5 XL (Thermo Fisher Scientific, Waltham, MA, USA). We compared two bioinformatics pipelines for optimal processing of S5 XL sequence data: the Torrent Suite with a plug-in Torrent Variant Caller (Thermo Fisher Scientific), and commercial NextGENe software (Softgenetics, State College, PA, USA). All expected 681 single nucleotide variants, 15 small indels, and three copy number variants were correctly called, except one common variant adjacent to a rare variant on the primer-binding site. The sensitivity, specificity, false positive rate, and accuracy for detection of single nucleotide variant and small indels of S5 XL sequencing were 99.85%, 100%, 0%, and 99.99% for the Torrent Variant Caller and 99.85%, 99.99%, 0.14%, and 99.99% for NextGENe, respectively. The reproducibility of variant calling was 100%, and the precision of variant frequency also showed good performance with coefficients of variation between 0.32 and 5.29%. We obtained highly accurate data through uniform and sufficient coverage depth over all target regions and through optimization of the bioinformatics pipeline. We confirmed that our platform is accurate and practical for diagnostic BRCA1/2 testing in a clinical laboratory.

AB - In this study, we validated the analytical performance of BRCA1/2 sequencing using Ion Torrent's new bench-top sequencer with amplicon panel with optimized bioinformatics pipelines. Using 43 samples that were previously validated by Illumina's MiSeq platform and/or by Sanger sequencing/multiplex ligation-dependent probe amplification, we amplified the target with the Oncomine™ BRCA Research Assay and sequenced on Ion Torrent S5 XL (Thermo Fisher Scientific, Waltham, MA, USA). We compared two bioinformatics pipelines for optimal processing of S5 XL sequence data: the Torrent Suite with a plug-in Torrent Variant Caller (Thermo Fisher Scientific), and commercial NextGENe software (Softgenetics, State College, PA, USA). All expected 681 single nucleotide variants, 15 small indels, and three copy number variants were correctly called, except one common variant adjacent to a rare variant on the primer-binding site. The sensitivity, specificity, false positive rate, and accuracy for detection of single nucleotide variant and small indels of S5 XL sequencing were 99.85%, 100%, 0%, and 99.99% for the Torrent Variant Caller and 99.85%, 99.99%, 0.14%, and 99.99% for NextGENe, respectively. The reproducibility of variant calling was 100%, and the precision of variant frequency also showed good performance with coefficients of variation between 0.32 and 5.29%. We obtained highly accurate data through uniform and sufficient coverage depth over all target regions and through optimization of the bioinformatics pipeline. We confirmed that our platform is accurate and practical for diagnostic BRCA1/2 testing in a clinical laboratory.

UR - http://www.scopus.com/inward/record.url?scp=85019967118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019967118&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16799

DO - 10.18632/oncotarget.16799

M3 - Article

AN - SCOPUS:85019967118

VL - 8

SP - 34858

EP - 34866

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 21

ER -